About this study
In this clinical trial, we will study how well the medicine tegavivint treats certain solid tumors that have come back after treatment (relapsed) or did not respond to treatment (refractory).
Tegavivint has been studied in adults with cancer. We will study how well it works in children, teens, and young adults. This drug helps block a certain cell pathway that is important in the growth of cancer cells. We will study this medicine in children and young adults who have:
- Ewing sarcoma
- Desmoid tumors
- Osteosarcoma
- Liver tumors
- Wilms tumor
- Tumors with a genetic change (mutation) in a gene called Wnt
There are 2 phases, or parts, to this clinical trial:
- Phase 1 (or Part A) is complete. It helped us decide the best dose of tegavivint to use, and we studied the side effects.
- Phase 2 (or Part B) is now open to accept eligible patients. We will use the dose we decided on in phase 1 to study how well tegavivint works.
Purpose of this clinical trial
The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.
Eligibility overview
To take part in this study, you must be:
- 12 months to 30 years old
- Have a recurrent or refractory solid tumor, including non-Hodgkin lymphoma or desmoid tumor
- For phase 2: you must have recurrent or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor (hepatocellular carcinoma or hepatoblastoma), Wilms tumor, or a tumor that has certain changes in the Wnt gene.